DOI:
10.1055/s-00000003
Aktuelle Ernährungsmedizin
LinksClose Window
References
Hensen J, Howard CP, Walter V. et al.
Impact of interleukin-1beta antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial.
Diabetes Metab 2013;
39: 524-531
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.